BioCentury | Jan 31, 2020
Distillery Therapeutics

Inhibiting SPK2 to treat Middle East respiratory syndrome

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus SKP2 inhibition could treat Middle East respiratory syndrome (MERS) coronavirus infection by reducing degradation of BECN, an autophagy regulator. In cell-based assays, MERS coronavirus infection induced SKP2 phosphorylation and...
BC Extra | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BC Extra | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells  Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
BC Innovations | May 20, 2019
Distillery Therapeutics

HIST4H4 inhibition to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Mouse studies suggest inhibiting HIST4H4 or its interaction with the cell membrane could help treat atherosclerosis. In a mouse model of atherosclerosis, a mAb against HIST4H4 or a cyclical peptide...
BC Innovations | Jan 30, 2019
Distillery Therapeutics

Neurology; cardiovascular

INDICATION: Alzheimer's disease (AD); atherosclerosis Mouse studies suggest inhibiting C5 could help treat AD and atherosclerosis. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
BC Innovations | Jan 23, 2019
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BC Innovations | Nov 1, 2018
Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
BC Innovations | Jun 14, 2018
Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
BC Innovations | Jun 5, 2018
Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced...
Items per page:
1 - 10 of 37
BioCentury | Jan 31, 2020
Distillery Therapeutics

Inhibiting SPK2 to treat Middle East respiratory syndrome

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus SKP2 inhibition could treat Middle East respiratory syndrome (MERS) coronavirus infection by reducing degradation of BECN, an autophagy regulator. In cell-based assays, MERS coronavirus infection induced SKP2 phosphorylation and...
BC Extra | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BC Extra | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells  Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
BC Innovations | May 20, 2019
Distillery Therapeutics

HIST4H4 inhibition to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Mouse studies suggest inhibiting HIST4H4 or its interaction with the cell membrane could help treat atherosclerosis. In a mouse model of atherosclerosis, a mAb against HIST4H4 or a cyclical peptide...
BC Innovations | Jan 30, 2019
Distillery Therapeutics

Neurology; cardiovascular

INDICATION: Alzheimer's disease (AD); atherosclerosis Mouse studies suggest inhibiting C5 could help treat AD and atherosclerosis. In a transgenic mouse model of AD expressing mutant human amyloid precursor protein (APP) and presenilin 1 (PSEN1; PS1),...
BC Innovations | Jan 23, 2019
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BC Innovations | Nov 1, 2018
Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
BC Innovations | Jun 14, 2018
Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
BC Innovations | Jun 5, 2018
Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced...
Items per page:
1 - 10 of 37